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DOI 10.1016/j.cmet.2012.02.007The points raised by Dupuis, Petersen,
and Weydt (Dupuis et al., 2012)
regarding our findings (Matsubara et al.,
2012) are intriguing. We found that
PGRN-deficient mice exhibit decreased
body weight, increased insulin sensitivity,
and decreased respiratory quotient
compared to wild-type mice only when
they are exposed to high-fat diet (HFD);
there are no differences in these meta-
bolic parameters between wild-type
mice and PGRN-deficient mice under
normal chow conditions. This suggests
that ablation of PGRN suppresses HFD-
induced obesity by consuming lipids
more preferentially than carbohydrates.
It will be interesting to study the effects
of dietary factors, e.g., HFD, on energy
metabolism and insulin sensitivity in
fronto-temporal dementia (FTD) in a clin-
ical setting.
Dupuis, Petersen, and Weydt mention
that inducers of PGRN secretion, which
are candidate drugs to yield neuropro-
tection, might cause insulin resistance.
Our data also suggest a related process:inhibitors of PGRN secretion and/or
antagonists of PGRN used to protect
against insulin resistance and obesity
might impair the neuroprotective effect
of PGRN. In these cases, tissue-specific
PGRN inducers or blockers might be
considered, according to disease state.
Apart from loss-of-function mutations
in FTD, increased levels of PGRN expres-
sion in the brain have been reported in
amyotrophic lateral sclerosis, Alzheimer’s
disease, and Creutzfeldt-Jakob disease
(Cruts and Van Broeckhoven, 2008).
Accumulating evidence indicates that
insulin resistance and type 2 diabetes are
associated with the pathogenesis and
pathophysiology of neurodegenerative
diseases in humans (Luchsinger and Gus-
tafson, 2009). In addition, a recent paper
has shown that impairment of insulin
signaling in brain induces hyperphosphor-
ylation of Tau, a hallmark of neurodegen-
erative diseases (Kim and Feldman,
2012). Since PGRN directly inhibits insulin
signaling in adipocytes, high levels of
PGRN in brain might impair insulinsignaling in neuronal cells and contribute
to the pathogenesis and pathophysiology
of certain neurodegenerative diseases.
We agree that identification of PGRN
as a causative factor for impaired insulin
signaling opens the way to investigations
of the mechanisms linking insulin re-
sistance, type 2 diabetes, and neuro-
degenerative diseases as well as the
mechanisms of HFD-induced obesity.REFERENCES
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